-53%

est. 2Y upside i

HealthcareSeries B

Rank

#3300

Sector

HealthTech

Est. Liquidity

~2Y

Data Quality

Data: Medium

Given a stale $600M valuation from 2021 and lack of growth data, Notable's equity offers poor risk-reward over 2 years.

Last updated: July 19, 2026

Bull (10%)+2%

Driven by an exit multiple of 12x, the implied exit value is $730M. After 20% dilution from anticipated fundraising, net upside is 1.7%.

Base (45%)-39%

With a 8x exit multiple, the implied exit value is $487M, yielding a -18.9% pre-dilution return. After 20% dilution, the net downside is -38.9%.

Bear (45%)-79%

Assuming a compressed 4x multiple, the exit value drops to $243M. Dilution further reduces the return to -79.4%.

Est. time to liquidity~2.0 years

Preference Stack Risk

high

Funding Intensity

29880%

Total preferred liquidation preference of $127M represents 21% of the $600M valuation, giving preferred a significant cushion.

Dilution Risk

high

No recent funding for 4.5 years suggests a raise is probable; 20% dilution is assumed.

Secondary Liquidity

none

No secondary transactions reported.

Engineering — 6 roles

Delivery — 2 roles

Marketing — 2 roles

Partnerships/Sales — 2 roles

Product — 1 role

Solutions — 1 role

View all 14 open roles at Notable →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Notable's data — designed to show you've done your homework.

  • 1

    “How does Notable's AI platform differentiate from Epic's native automation features?”

  • 2

    “What is the path to profitability given current burn and no recent funding round?”

  • 3

    “What triggers a secondary market transaction today, and how does that affect equity liquidity for employees?”

Community

Valuation Sentiment

Our model estimates -53% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.